AAP
ADCT icon

Arax Advisory Partners’s ADC Therapeutics ADCT Stock Holding History

Arax Advisory Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17
Closed -$60 – 3774
2025
Q4 		$60 Sell
17
-655
-97% -$2.66K ﹤0.01% 3893
2025
Q3 		$2.69K Buy
+672
New +$2.12K ﹤0.01% 3039

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arax Advisory Partners's ADCT Position: Q1 2026 in Review

Arax Advisory Partners sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 17 shares — an estimated $60 sold.

Arax Advisory Partners first reported a position in ADCT in Q3 2025 and held it in 2 quarters. The position peaked at $2.69K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Arax Advisory Partners reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 17 ADC Therapeutics shares in Q1 2026, an estimated $60.
  • Arax Advisory Partners first reported a position in ADC Therapeutics in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's ADC Therapeutics position peaked at $2.69K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.